A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

NCT07123519 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)
Lupus Nephritis (LN)
Sjogren's Syndrome (SS)
Inflammatory Myopathy
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antiphospholipid Syndrome (APS)

Interventions

DRUG: YTS109 cell

Sponsor

China Immunotech (Beijing) Biotechnology Co., Ltd.

Collaborators

[object Object]